Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England

Glaxosmithkline Share News (GSK)

Stock Market news at - RSS News Feeds

Share News for Glaxosmithkline (GSK)

Share Price: 1,582.00Bid: 1,581.20Ask: 1,581.60Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.40Spread as %: 0.03%Open: 1,577.60High: 1,586.80Low: 1,570.60Yesterday’s Close: 1,582.00

Gene test for asthmatic kids helps target treatment

Tue, 8th Jan 2013 00:16

By Kate Kelland

LONDON, Jan 8 (Reuters) - Testing children with asthm
a for a specific gene could help doctors avoid giving them common inhaler medicines that are unlikely to help and may make their condition worse, scientists said on Tuesday.

British researchers studying why certain asthma drugs taken by millions of children don't appear to benefit some patients said a gene called arginine-16 (Arg16) is key to determining which medicines work for some and not for others.

Having a particular change in this gene means a drug called salmeterol, a generic drug used in GlaxoSmithKline's (GSK) Advair, Serevent and Seretide treatments, is unlikely to improve the condition and may exacerbate it, the scientists said.

'We have for the first time shown that personalised medicine can work in the field of children's asthma,' said Somnath Mukhopadhyay of Brighton and Sussex Medical School, who led the work and presented his findings at a briefing in London.

Asthma affects more than 300 million people globally and is the world's most common children's chronic illness. Symptoms include wheezing, shortness of breath, coughing and chest tightness. Many children are prescribed salmeterol, a long-acting so-called beta-receptor stimulant, to ease symptoms.

But after finding in a large observational study published in 2009 that some children fail to respond to salmeterol, and linking that to the Arg16 gene, Mukhopadhyay's team decided to look closer. They conducted a genotyped study comparing salmeterol with another generic drug called montelukast.

The researchers took 62 children with asthma who had the susceptible Arg16 genotype and who were still having problems despite using regular steroid preventer inhaler medicines.

The children were then randomly assigned to get either salmeterol or montelukast along with their inhaler, and researchers tracked their progress for a year.

'For almost every symptom we looked at there was a significant difference, and it was always not in favour of salmeterol,' Mukhopadhyay said. 'These are striking findings.'

A spokesman for GSK said that Serevent, which was first licensed in 1990, has since 'become one of the most extensively studied asthma medicines' with 'a wealth of evidence to support its effectiveness when used appropriately'.

'The results of this small study raise interesting questions around how different patients can gain the most benefit from their medicines and it warrants further research,' he said.

More than a million children in Britain have asthma and some 150,000 of them have the Arg16 gene change that makes them less likely to respond to salmeterol.

The researchers, whose study was published in the journal Clinical Science on Tuesday, warned that many children around the world with serious asthma who are taking salmeterol but not benefiting from it may be suffering needlessly.

A genetic test which Mukhopadhyay said would cost around 15 pounds ($24) could reveal why, and point doctors to the most effective treatments.

Experts commenting on the findings said they were intriguing and important.

'This is a wonderful example of...personalised medicine working its way into practice,' said Stephen Holgate of Southampton University. He said that while the genetic test is not yet available to family doctors, it should be if larger trials find the same results.

Malayka Rahman of the charity Asthma UK agreed further trials are needed to establish whether large-scale Arg16 genetic screening in asthma patients should be introduced.

She also called for more research into genes that affect responses to asthma treatments: 'This... area of research has the potential to lead to the tailoring of better treatments for an individual based on their own genetic make-up - ultimately keeping more people out of hospital and preventing unnecessary asthma deaths,' she said.

($1 = 0.6236 British pounds)

(Reporting by Kate Kelland; editing by Jason Neely) Keywords: ASTHMA INHALERS/

( 542 0823)(Reuters Messaging:

Copyright Thomson Reuters 2013. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

UPDATE 1-GSK brings back bonuses for some sales reps

(Adds background on bribery scandals and fines)May 23 (Reuters) - British drugmaker GlaxoSmithKline said on Thursday it will reintroduce incentive pay
[23 May '19 18:07]

GSK to change incentives for sales representatives

May 23 (Reuters) - British drugmaker GlaxoSmithKline said on Thursday it will change incentives for sales representatives in some countries as it look
[23 May '19 15:21]

UPDATE 1-Amgen to buy Copenhagen-based Nuevolution for $167 mln

(Adds detail, background, shares)May 22 (Reuters) - Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharm
[22 May '19 09:54]

UPDATE 2-Brexit worries hit domestic stocks but sterling slide lifts FTSE 100

* FTSE 100 up 0.1%, FTSE 250 down 0.7%* Exporters top boost to main index* Brexit-sensitive stocks slip* M&S slumps after discounted offering* IG gain
[22 May '19 09:33]

Trade rhetoric weighs on European shares

(For a live blog on European stocks, type LIVE/ in an Eikon news window)May 17 (Reuters) - European shares dropped on Friday after three days of gains
[17 May '19 08:03]

Ex-divs to take 23.6 points off FTSE 100 on May 16

MILAN, May 13 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the lates
[13 May '19 09:55]

UK regulator investigates China's state broadcaster for airing TV confession

LONDON, May 8 (Reuters) - Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aire
[8 May '19 15:14]

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 (Reuters) - British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc i
[4 May '19 17:24]

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.